154 related articles for article (PubMed ID: 28855026)
1. Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells.
You D; Jung SP; Jeong Y; Bae SY; Lee JE; Kim S
BMB Rep; 2017 Dec; 50(12):615-620. PubMed ID: 28855026
[TBL] [Abstract][Full Text] [Related]
2. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells.
Kim S; Jeon M; Lee JE; Nam SJ
Oncol Rep; 2016 Apr; 35(4):2398-404. PubMed ID: 26780941
[TBL] [Abstract][Full Text] [Related]
3. Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells.
Kim S; Oh SJ; Lee J; Han J; Jeon M; Jung T; Lee SK; Bae SY; Kim J; Gil WH; Kim SW; Lee JE; Nam SJ
Cell Physiol Biochem; 2013; 32(5):1541-50. PubMed ID: 24335179
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
5. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
[TBL] [Abstract][Full Text] [Related]
6. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
Yang S; Lee JY; Hur H; Oh JH; Kim MH
BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
[TBL] [Abstract][Full Text] [Related]
8. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
[TBL] [Abstract][Full Text] [Related]
10. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
12. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.
Campbell PS; Mavingire N; Khan S; Rowland LK; Wooten JV; Opoku-Agyeman A; Guevara A; Soto U; Cavalli F; Loaiza-Pérez AI; Nagaraj G; Denham LJ; Adeoye O; Jenkins BD; Davis MB; Schiff R; Brantley EJ
J Cell Physiol; 2018 Jan; 234(1):108-121. PubMed ID: 30076704
[TBL] [Abstract][Full Text] [Related]
13. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
Wu C; Luo J
Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
[TBL] [Abstract][Full Text] [Related]
14. TP53 upregulates α‑smooth muscle actin expression in tamoxifen‑resistant breast cancer cells.
Kim S; You D; Jeong Y; Yu J; Kim SW; Nam SJ; Lee JE
Oncol Rep; 2019 Feb; 41(2):1075-1082. PubMed ID: 30535478
[TBL] [Abstract][Full Text] [Related]
15. Aromatase induction in tamoxifen-resistant breast cancer: Role of phosphoinositide 3-kinase-dependent CREB activation.
Phuong NT; Lim SC; Kim YM; Kang KW
Cancer Lett; 2014 Aug; 351(1):91-9. PubMed ID: 24836190
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
[TBL] [Abstract][Full Text] [Related]
17. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
Li Z; Yu D; Li H; Lv Y; Li S
Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
[TBL] [Abstract][Full Text] [Related]
18. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
19. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.
Lee KY; Lee JW; Nam HJ; Shim JH; Song Y; Kang KW
Mol Cells; 2011 Jul; 32(1):107-11. PubMed ID: 21573702
[TBL] [Abstract][Full Text] [Related]
20. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
